Intracameral mydriatics in phacoemulsification XXXX surgery.

@entity1 @entity231 @entity4 @entity2647 @entity3303 @entity14433 @entity158 @entity5564
PURPOSE: To evaluate intracameral injection of mydriatics in phacoemulsification @entity231 surgery and compare the results with those of conventional topical mydriatics. SETTING: Department of Clinical Science/Ophthalmology, Ume   University Hospital, Ume  , Sweden. METHODS: This prospective randomized double-blind study included 60 @entity1 who were given topical (topical group) or intracameral (intracameral group) mydriatics. The topical mydriatics comprised 3 drops of @entity14433 1% and @entity2647 10% given 15 minutes apart and 150 microL intracameral @entity3303 1% ( @entity3303 ) and the intracameral mydriatics, placebo eyedrops and 150 microL intracameral cyclopentolate 0.1%, @entity2647 1.5%, and @entity3303 1%. The pupil size was recorded preoperatively, throughout surgery, and 1 day and 1 month postoperatively. Preoperative and postoperative corneal endothelial morphology, corneal thickness, intraocular pressure, visual acuity, aqueous cells and flare, phacoemulsification energy, duration of surgery, pulse, blood pressure, and intraoperative sensation of @entity158 and glare were also recorded. RESULTS: With intracameral mydriatics, @entity5564 reached 95% +/- 3% (SD) of its final value within 20 seconds. In the intracameral group, the pupils were smaller than in the topical group (mean 6.7 +/- 1.0 mm versus 7.7 +/- 1.0 mm, P<.001) but did not contract intraoperatively. The pupils in the topical group tended to contract, and the difference between groups was significant (P =.0020). The intracameral group reported less glare during the procedure (P<.001). There was no difference in endothelial cell loss, inflammatory reaction, postoperative @entity4 , or surgical performance between the groups. CONCLUSIONS: Intracameral mydriatics were a rapid, effective, and safe alternative to topical mydriatics in phacoemulsification. Their use can simplify preoperative routines and in certain high-risk groups, may reduce the risk for cardiovascular side effects.
